JAMA Network | JAMA | Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies

JAMA Network | JAMA | Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies

Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies FREE

Julie A. Jacob, MA

JAMA. 2015;314(20):2117-2119. doi:10.1001/jama.2015.10795.

Text Size: A A A

Article

Figures

The origins of cancer immunotherapy date back more than 2 decades to when researchers explored ways to amplify the immune system to attack tumor cells. At the time, scientists hypothesized that tumors were able to evade immune surveillance because tumor cells lacked costimulatory molecules required to signal T cells to the presence of the tumor.

PD-1 and CTLA-4 checkpoint inhibitors prevent tumor cells and antigen presenting cells, respectively, from suppressing tumor-reactive T-cell function.

However, in the mid-1990s, James P. Allison, PhD, and his colleagues at the University of California, Berkeley, Cancer Research Laboratory discovered that rather than lack costimulatory molecules, tumor cells and other immune cells expressed inhibitory molecules that disabled T cells from recognizing and eliminating tumors.